New strategies for the treatment of carcinoma of unknown primary.
10.3760/cma.j.cn112152-20220128-00068
- Author:
Li Xi LI
1
;
Di ZHANG
1
;
Fei MA
1
Author Information
1. Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
- Publication Type:Journal Article
- Keywords:
Basket trial;
Carcinoma of unknown primary;
Chemotherapy;
Immunotherapy;
Poor prognosis subtype;
Targeted therapy
- MeSH:
Humans;
Neoplasms, Unknown Primary/genetics*;
Carcinoma/drug therapy*;
Gene Expression Profiling/methods*;
Microarray Analysis;
Prognosis
- From:
Chinese Journal of Oncology
2023;45(1):44-49
- CountryChina
- Language:Chinese
-
Abstract:
Carcinoma of unknown primary (CUP) is a kind of metastatic tumor whose primary origin cannot be identified after adequate examination and evaluation. The main treatment modality of CUP is empiric chemotherapy, and the median overall survival time is less than 1 year. Compared with immunohistochemistry, novel method based on gene expression profiling have improved the sensitivity and specificity of CUP detection, but its guiding value for treatment is still controversial. The approval of immune checkpoint inhibitors and pan-cancer antitumor agents has improved the prognosis of patients with CUP, and targeted therapy and immunotherapy based on specific molecular characteristics are the main directions of future research. Given the high heterogeneity and unique clinicopathological characteristics of CUP, "basket trial" is more suitable for clinical trial design in CUP.
